According to Zacks, “Entasis Therapeutics Holdings Inc. produces, researches and develops antibacterial therapies and drugs through its subsidiaries. The company’s product pipeline consists of etx2514sul, zoliflodacin, etx0282cpdp and nbp program which are in clinical stage. Entasis Therapeutics Holdings, Inc. is based in Waltham, Massachusetts. “
Several other analysts have also issued reports on ETTX. ValuEngine upgraded shares of Entasis Therapeutics from a hold rating to a buy rating in a research note on Thursday, August 8th. HC Wainwright initiated coverage on shares of Entasis Therapeutics in a research note on Monday, August 19th. They issued a buy rating and a $18.00 target price for the company. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Entasis Therapeutics has a consensus rating of Buy and a consensus price target of $16.75.
Entasis Therapeutics (NASDAQ:ETTX) last posted its earnings results on Monday, August 12th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.44). On average, research analysts anticipate that Entasis Therapeutics will post -4.03 EPS for the current fiscal year.
A hedge fund recently raised its stake in Entasis Therapeutics stock. Janney Montgomery Scott LLC boosted its stake in shares of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) by 5.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,917 shares of the company’s stock after buying an additional 2,125 shares during the quarter. Janney Montgomery Scott LLC owned approximately 0.34% of Entasis Therapeutics worth $290,000 as of its most recent SEC filing. 64.99% of the stock is owned by hedge funds and other institutional investors.
About Entasis Therapeutics
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Recommended Story: Call Option Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.